Liraglutide (LG), one of the limited number of obesity drugs in our country, is a long-acting GLP-1 receptor agonist (GLP-1 RA) that is resistant to metabolism by the dipeptidyl peptidase (DPP)-IV enzyme [6]. Here, GLP1R is linked to obesity disorder.